`
`(Reference Data of Financial Statements for the 3Q of Fiscal 2015)
`
`February 5, 2016
`
`KAKEN PHARMACEUTICAL CO., LTD.
`
` Corporate Communications
` Tel:
` +81-(0)3-5977-5002
` Fax:
` +81-(0)3-5977-5131
` Email:
` koho@kaken.co.jp
`
`Page 1 of 2
`
`ACRUX DDS PTY LTD. et al.
`
`EXHIBIT 1648
`
`IPR Petition for
`
`U.S. Patent No. 7,214,506
`
`
`
`1. Summary of Consolidated Financial Statements for the Third Quarter of Fiscal 2015
`
`( Figures less than one million yen have been omitted)
`
`FY2014
`3rd Q
`
`FY2014
`
`FY2015
`3rd Q
`
`Net sales
`
`Operating income
`
`71,155
`
`16,611
`
`93,889
`
`20,631
`
`85,431
`
`29,689
`
` Ratio of net sales
`
`23.3%
`
`22.0%
`
`34.8%
`
`Yen
`
`14,275
`
`13,077
`
`Y o Y increase (decrease)
`
`FY2015
`Forecasts
`
`%
`
`120.1% 107,900
`
`178.7%
`
`32,200
`
`29.8%
`
`Y o Y increase (decrease)
`
`Yen
`
`14,011
`
`11,569
`
`%
`
`114.9%
`
`156.1%
`
`Ordinary income
`
`16,474
`
`20,394
`
`29,919
`
`13,445
`
`181.6%
`
`32,400
`
`12,006
`
`158.9%
`
` Ratio of net sales
`
`23.2%
`
`21.7%
`
`35.0%
`
`30.0%
`
`Net income
`
`9,605
`
`12,122
`
`20,134
`
`10,529
`
`209.6%
`
`19,200
`
`7,078
`
`158.4%
`
` Ratio of net sales
`
`13.5%
`
`12.9%
`
`23.6%
`
`17.8%
`
`Comprehensive income
`
`11,650
`
`16,607
`
`20,711
`
`9,061
`
`177.8%
`
`R&D expenses
`
`4,806
`
`7,615
`
`4,392
`
`(413)
`
`91.4%
`
`8,300
`
`685
`
`109.0%
`
`2. Breakdown of Sales by Main Pharmaceuticals and Medical Devices
`
`( Figures less than one million yen have been omitted)
`
`FY2014
`3rd Q
`
`FY2014
`
`FY2015
`3rd Q
`
`%
`
`FY2015
`Forecasts
`
`%
`
`23,922
`
`30,259
`
`24,250
`
`101.4%
`
`30,600
`
`101.1%
`
`4,039
`
`6,857
`
`15,385
`
`380.9%
`
`18,500
`
`269.8%
`
`8,425
`
`10,791
`
`8,711
`
`103.4%
`
`11,200
`
`103.8%
`
`3,361
`
`4,373
`
`3,495
`
`104.0%
`
`4,600
`
`105.2%
`
`2,623
`
`3,511
`
`2,723
`
`103.8%
`
`3,600
`
`102.5%
`
`Anti-osteoarthritis
`Artz
`
`Anti-nail fungus
`Clenafin
`
`Post-operative anti-adhesive
`Seprafilm
`
`Anti-hyperlipidemia
`Lipidil
`
`Wound healing agent
`Fiblast Spray
`
`Generic products
`
`9,479
`
`12,380
`
`10,237
`
`108.0%
`
`13,300
`
`107.4%
`
`Sales of Jublia*
`
`2,386
`
`3,318
`
`4,986
`
`209.0%
`
`5,600
`
`168.8%
`
`(* including sales of API and finished product, royalty revenue and milestone revenue)
`
`KAKEN PHARMACEUTICAL CO., LTD.
`
`Page 2 of 2
`
`